Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:COGT NASDAQ:INSM NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$91.09+2.0%$91.33$79.52▼$124.00$22.59B1.32732,277 shs686,610 shsCOGTCogent Biosciences$40.44+1.7%$36.04$10.38▼$43.73$6.79B0.342.39 million shs1.38 million shsINSMInsmed$104.73-2.0%$105.15$90.39▼$212.75$23.18B0.782.28 million shs1.90 million shsROIVRoivant Sciences$34.72-0.8%$32.36$10.90▼$37.00$25.18B1.114.58 million shs4.27 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech+1.97%-1.16%-0.14%-10.75%-21.00%COGTCogent Biosciences+1.71%+5.59%+6.10%+11.28%+235.05%INSMInsmed-2.05%-2.14%+1.31%-22.39%+0.75%ROIVRoivant Sciences-0.83%+1.97%+1.91%+25.03%+200.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$91.09+2.0%$91.33$79.52▼$124.00$22.59B1.32732,277 shs686,610 shsCOGTCogent Biosciences$40.44+1.7%$36.04$10.38▼$43.73$6.79B0.342.39 million shs1.38 million shsINSMInsmed$104.73-2.0%$105.15$90.39▼$212.75$23.18B0.782.28 million shs1.90 million shsROIVRoivant Sciences$34.72-0.8%$32.36$10.90▼$37.00$25.18B1.114.58 million shs4.27 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech+1.97%-1.16%-0.14%-10.75%-21.00%COGTCogent Biosciences+1.71%+5.59%+6.10%+11.28%+235.05%INSMInsmed-2.05%-2.14%+1.31%-22.39%+0.75%ROIVRoivant Sciences-0.83%+1.97%+1.91%+25.03%+200.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.74Moderate Buy$129.1341.76% UpsideCOGTCogent Biosciences 2.85Moderate Buy$45.9013.50% UpsideINSMInsmed 3.00Buy$209.1399.69% UpsideROIVRoivant Sciences 2.75Moderate Buy$33.59-3.25% DownsideCurrent Analyst Ratings BreakdownLatest COGT, ROIV, BNTX, and INSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026INSMInsmed BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$192.007/20/2026INSMInsmed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$220.007/20/2026INSMInsmed BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/17/2026INSMInsmed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026INSMInsmed Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$160.00 ➝ $161.007/10/2026INSMInsmed GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$207.007/8/2026COGTCogent Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/8/2026BNTXBioNTech Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$126.00 ➝ $119.007/6/2026BNTXBioNTech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/16/2026INSMInsmed MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$192.006/10/2026INSMInsmed Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.81B8.21$1.36 per share66.91$96.59 per share0.94COGTCogent BiosciencesN/AN/AN/AN/A$3.84 per shareN/AINSMInsmed$606.42M37.43N/AN/A$3.46 per share30.27ROIVRoivant Sciences$8.26M3,023.37N/AN/A$7.35 per share4.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/4/2026 (Estimated)COGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)INSMInsmed-$1.28B-$5.75N/A177.51N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)ROIVRoivant Sciences-$299.77M-$0.60N/AN/AN/A-3,629.19%-20.54%-19.43%8/6/2026 (Estimated)Latest COGT, ROIV, BNTX, and INSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026INSMInsmed-$0.69N/AN/AN/A$393.40 millionN/A8/6/2026Q1 2027ROIVRoivant Sciences-$0.33N/AN/AN/A$2.00 millionN/A8/4/2026Q2 2026BNTXBioNTech-$2.3999N/AN/AN/A$183.75 millionN/A8/4/2026Q2 2026COGTCogent Biosciences-$0.55N/AN/AN/A$0.00 millionN/A5/7/2026Q1 2026INSMInsmed-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/A5/4/2026Q1 2026BNTXBioNTech-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTech$1.531.68%N/AN/A N/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.808.74COGTCogent Biosciences0.4115.1415.14INSMInsmed0.804.474.10ROIVRoivant SciencesN/A18.3718.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%COGTCogent BiosciencesN/AINSMInsmedN/AROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%COGTCogent Biosciences6.59%INSMInsmed2.10%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech7,807252.88 million204.33 millionOptionableCOGTCogent Biosciences80170.87 million159.61 millionOptionableINSMInsmed1,664216.75 million212.20 millionOptionableROIVRoivant Sciences860719.27 million641.59 millionOptionableCOGT, ROIV, BNTX, and INSM HeadlinesRecent News About These CompaniesMaverick Capital Ltd. Takes $45.07 Million Position in Roivant Sciences Ltd. $ROIV35 minutes ago | marketbeat.comRoivant Sciences (ROIV) Receives a Buy from Piper SandlerJuly 26 at 6:19 AM | theglobeandmail.comDimensional Fund Advisors LP Sells 1,771,602 Shares of Roivant Sciences Ltd. $ROIVJuly 25 at 3:37 AM | marketbeat.comBank of Nova Scotia Cuts Stake in Roivant Sciences Ltd. $ROIVJuly 25 at 3:21 AM | marketbeat.comAllspring Global Investments Holdings LLC Buys New Stake in Roivant Sciences Ltd. $ROIVJuly 25 at 3:05 AM | marketbeat.comRoivant Sciences Ltd. $ROIV Stake Boosted by Affinity Asset Advisors LLCJuly 25 at 3:04 AM | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 24, 2026 | marketbeat.comCalifornia Public Employees Retirement System Invests $19.15 Million in Roivant Sciences Ltd. $ROIVJuly 24, 2026 | marketbeat.comImmunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026July 23, 2026 | globenewswire.comBaader Bank Aktiengesellschaft Sells 33,612 Shares of Roivant Sciences Ltd. $ROIVJuly 23, 2026 | marketbeat.comBank of New York Mellon Corp Decreases Stock Holdings in Roivant Sciences Ltd. $ROIVJuly 22, 2026 | marketbeat.comBillionaire Ramaswamy's wealth has surged as he runs for Ohio governorJuly 21, 2026 | usatoday.comJennison Associates LLC Boosts Holdings in Roivant Sciences Ltd. $ROIVJuly 20, 2026 | marketbeat.comIllinois Municipal Retirement Fund Boosts Stake in Roivant Sciences Ltd. $ROIVJuly 20, 2026 | marketbeat.comPrincipal Financial Group Inc. Boosts Holdings in Roivant Sciences Ltd. $ROIVJuly 20, 2026 | marketbeat.comOhio Chamber wrong. Vivek Ramaswamy's love of money won't create jobs here | LettersJuly 18, 2026 | msn.comRoivant Sciences Ltd. $ROIV Stake Raised by Dorsey Wright & AssociatesJuly 18, 2026 | marketbeat.comABUS stock on track for best day in about two months — what’s the Moderna connection?July 16, 2026 | msn.comPfizer, BioNTech face global patent suits from Arbutus, Roivant over COVID vaccine techJuly 16, 2026 | msn.comThree Seasons Wealth LLC Invests $819,000 in Roivant Sciences Ltd. $ROIVJuly 16, 2026 | marketbeat.comHsbc Holdings PLC Invests $896,000 in Roivant Sciences Ltd. $ROIVJuly 15, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOGT, ROIV, BNTX, and INSM Company DescriptionsBioNTech NASDAQ:BNTX$91.09 +1.76 (+1.97%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$91.36 +0.27 (+0.30%) As of 06:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Cogent Biosciences NASDAQ:COGT$40.44 +0.68 (+1.71%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$40.30 -0.14 (-0.35%) As of 04:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Insmed NASDAQ:INSM$104.73 -2.19 (-2.05%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$105.12 +0.39 (+0.38%) As of 06:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Roivant Sciences NASDAQ:ROIV$34.72 -0.29 (-0.83%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$34.86 +0.14 (+0.40%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now AMD’s AI Bubble Could Burst Into Explosive Upside Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? A $1.5 Billion Wake-Up Call for Every AI Company on Wall Street AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight Apple’s Earnings Setup Puts Its Record Rally and AI Patience to the Test Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
